Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Update

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the recipient of a significant increase in short interest in June. As of June 30th, there was short interest totaling 137,273 shares, an increase of 310.9% from the June 15th total of 33,404 shares. Approximately 24.6% of the shares of the stock are short sold. Based on an average daily volume of 4,260,794 shares, the short-interest ratio is presently 0.0 days.

Shuttle Pharmaceuticals Stock Up 1.4%

Shuttle Pharmaceuticals stock traded up $0.04 during mid-day trading on Monday, reaching $2.96. 12,456,514 shares of the company’s stock traded hands, compared to its average volume of 2,341,409. Shuttle Pharmaceuticals has a 12-month low of $2.71 and a 12-month high of $55.90. The stock has a 50 day moving average of $4.86 and a two-hundred day moving average of $9.96. The company has a market cap of $1.89 million, a price-to-earnings ratio of -0.06 and a beta of 0.29.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a research note on Saturday, July 4th. Weiss Ratings raised Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Insider Buying and Selling at Shuttle Pharmaceuticals

In other news, major shareholder Financial Lp Hrt bought 25,836 shares of Shuttle Pharmaceuticals stock in a transaction dated Monday, June 29th. The shares were purchased at an average cost of $3.44 per share, with a total value of $88,875.84. Following the completion of the acquisition, the insider owned 71,842 shares of the company’s stock, valued at $247,136.48. This trade represents a 56.16% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders bought 53,398 shares of company stock worth $181,764 and sold 38,133 shares worth $132,128. 12.60% of the stock is currently owned by insiders.

Institutional Trading of Shuttle Pharmaceuticals

Large investors have recently made changes to their positions in the business. Connective Capital Management LLC purchased a new stake in shares of Shuttle Pharmaceuticals during the 3rd quarter valued at about $357,000. Ikarian Capital LLC purchased a new position in Shuttle Pharmaceuticals in the fourth quarter worth about $124,000. Boothbay Fund Management LLC purchased a new position in Shuttle Pharmaceuticals in the fourth quarter worth about $37,000. Finally, Geode Capital Management LLC purchased a new position in Shuttle Pharmaceuticals in the fourth quarter worth about $26,000. 4.58% of the stock is currently owned by institutional investors.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .